Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells

Immunology Letters

Volumn 136, Issue 2, 2011, Pages 213-220

  Choi, Hyo jung ^a   Song, Suk yoon ^a   Yoon, Jae bong ^a   Liu, Li kun ^a   Kim, Kristine ^a   Cha, Sang hoon ^a  

^a Kangwon National University   (South Korea)

Author keywords

CD23; Cell panning; Dual vector system; Human antibody; IM 9; Phage display

Indexed keywords

CD23 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 4; LUMILIXIMAB; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOBLAST; BINDING AFFINITY; CLONE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA, B-CELL; PEPTIDE LIBRARY; PROTEIN BINDING; RECEPTORS, IGE; U937 CELLS;

EID: 79953024737     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.01.012     Document Type: Article

References (46)

1. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006, 7:S7-S13.
2. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2009, 440-449.
3. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD 59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
4. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinasedependent mechanism. Blood 2002, 99:1314-1319.
5. Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007, 33:710-728.
6. Keating M.J., O'Brien S., Kontoyiannis D., Plunkett W., Koller C., Beran M., et al. Results of first salvage therapy for patients refractory to a fludarabine regimer in chronic lymphocytic leukemia. Leuk Lymphoma 2002, 43:1755-1762.
7. ManShouri T., DoKA, Wang X., Giles F.J., O'Brien S.M., Safer H., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507-2513.
8. Moreton P., Kennedy B., Lucas G., Leach M., Rassam S., Haynes A., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzuman therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
9. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients repond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
10. Davis T.A., Grillo-Lopez A.J., White C.A., McLaughlin P., Czuczuman M.S., Link B.K., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000, 18:3135-3143.
11. Robak T., Jamroziak K., Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 2009, 69:2415-2449.
12. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008, 8:156-171.
13. Celeste Bello, Eduardo M., Sotomayer Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology 2007, 115:233-242.
14. Azzazy H.M., Highsmith W.E. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002, 35:425-445.
15. Marks J.D., Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol 2004, 248:161-176.
16. Hoogenboom H.R., Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000, 21:371-378.
17. Aires da Silva F., Corte-Real S., Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 2008, 22:301-314.
18. Giordano R.J., Cardó-Vila M., Lahdenranta K., Pasqualini R., Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001, 7:1249-1253.
19. Hur B., Yoon J., Liu L., Cha S. Isolation of a human anti-epidermal growth factor receptor Fab antibody EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system. Immunol Lett 2010, 134:55-61.
20. Hur B., Choi H., Song S., Yoon J., Liu L., Cha S. Development of the dual-vector system-III (DVS-III), which facilitates affinity maturation of a Fab antibody via light chain shuffling. Immunol Lett 2010, 132:24-30.
21. Joo H., Hur B., Lee K., Song S., Cha S. Establishment of a reliable dual-vector system for the phage display of antibody fragments. J Immunol Methods 2008, 333:24-27.
22. Brian KK, Jill W, John MC. Phage display of peptides and proteins, a laboratory manual. San Diego: Acadimic Press, P107.
23. Song S., Hur B., Lee K., Choi H., Kim S., Kang G., et al. Successful application of the dual-vector system II in creating reliable phage-displayed combinatorial Fab library. Mol Cells 2009, 3:313-319.
24. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988, 106:191-194.
25. Akahori Y., Kurosawa G., Sumitomo M., Morita M., Muramatsu C., Eguchi K., et al. Isolation of antigen/antibody complexes through organic solvent (ICOS) method. Biochem Biophy Res Commun 2009, 378:832-835.
26. Munoz O., Brignone C., Grenier-Brossette N., Bonnefoy J., Cousini J. Binding of anti-CD23 monoclonal antibody to the leucine zipper motif of FceRII/CD23 on B cell membrane promotes its proteolytic cleavage: evidence for an effect on the oligomer/monomer equilibrium. J Biol Chem 2005, 273:31795-31800.
27. Bonnefoy J., Aubry J., Peronne C., Wijdenes J., Banchereau A. Produciton and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE. J Immunol 1987, 138:2970-2978.
28. Fournier S., Delespesse G., Rubio M., Biron G., Sarfati M. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992, 89:1312-1321.
29. Nakamura T., Kloetzer W.S., Brams P., Hariharanb K., Chamatb S., Cao X., et al. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. Int J Immunopharmacol 2000, 22:131-141.
30. Chassagne S., Laffly E., Drouet E., Hérodin F., Lefranc M., Thullier P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol 2004, 41:539-546.
31. Byrd J.C., O'Brien S., Flinn I.W., Kipps T.J., Weiss M., Rai K., et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007, 13:4448-4455.
32. + lymphoma cell lines. Blood 2008, 111:1594-1602.
33. Smolej L. Modern concepts in the treatment of chronic lymphocytic leukemia. Hematology 2009, 14:249-254.
34. Byrd J.C., Kipps T.J., Flinn I.W., Castro J., Lin T.S., Wierda W., et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010, 115:489-495.
35. Marks J.D., Griffiths A.D., Malmqvist M., Clackson T.P., Bye J.M., Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY) 1992, 10:779-783.
36. Chowdhury P.S., Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999, 17:568-572.
37. Kamat V., Donaldson J.M., Kari C., Quadros M.R.D., Lelkes P.I., Chaiken I., et al. inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008, 7:726-733.
38. Kubetzko S., Balic E., Waibel R., Zangemeister-Wittke U., Plückthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006, 281:35186-35201.
39. Ouaaz F., Paul-Eugène1 N., Arock M., Merle-Béral H., Huerta J.M.M., Debré P., et al. Maturation of human myelomonocytic leukemia cells following ligation of the low affinity receptor for IgE (Fce{open}RII/CD23). Int Immunol 1993, 5:1251-1257.
40. So E., Kim S., Cho B., Park H., Lee C. Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity. FEBS Lett 2002, 518:53-59.
41. Zhang M., Murphy R.F., Agrawal D.K. Decoding IgE Fc receptors. Immunol Res 2007, 37:1-16.
42. Poole J.A., Meng J., Reff M., Spellman M.C., Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005, 116:780-788.
43. Rosenwasser L.J., Busse W.W., Lizambri R.G., Olejnik T.A., Totoritis M.C. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003, 112:563-570.
44. Rosenwasser L.J., Meng J. Anti-CD23. Clin Rev Allergy Immunol 2005, 29:61-72.
45. Wakai M., Pasley P., Sthoeger Z.M., Posnett D.N., Brooks R., Hashimoto S., et al. Anti-CD23 monoclonal antibodies: comparisons of epitope specificities and modulating capacities for IgE binding and production. Hybridoma 1993, 12:25-43.
46. Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol 2008, 8:205-217.